Application of Cancer Vaccines of IEPOR Series into Clinical Practice of Oncological Establishments of Ukraine

TitleApplication of Cancer Vaccines of IEPOR Series into Clinical Practice of Oncological Establishments of Ukraine
Publication TypeJournal Article
Year of Publication2009
AuthorsPotebnya, HP, Lisovenko, GS, Chekhun, VF
Short TitleNauka innov.
SectionScientific and Technical Innovative Projects of National Academy of Sciences of Ukraine
The article presents the review of clinical studies dealing with effectiveness of anticancer vaccines based on whole autologous or allogenic tumor cells or their lysates. The main results of clinical investigations of produced at R.Ye. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (National Academy of Sciences of Ukraine) anticancer vaccines based on autologous tumor cells and metabolic products of B.subtilis are described.
Keywordscancer vaccine, immunotherapy of cancer, oncological patients, survival
1. Berzofsky J.A., Terabe M., Oh S. et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004. 113(11): 1515-1525.
2. Rosenberg S. Progress in human tumor immunology and immunotherapy. Nature. 2001. 411(6835): 380-384.
3. Espinoza-Delgado I. Cancer vaccines. Oncologist. 2002. Vol. 7, Suppl. 3. P. 20-33.
4. Pandey M., Mathew A., Nair M.K. Cancer vaccine: a step toward prevention and treatment of cancer. Europ J Surg Oncol. 1999. Vol. 25. P. 209-214.
5. Armstrong A.C., Hawkins R.E. Vaccines in oncology: background and clinical potential. Brit J Radiol. 2001. 74(887): 991-1002.
6. Horig H., Kaufman H.L. Current issues in cancer vaccine development. Clin Immunol. 1999. 92(3): 211-223.
7. Slingluff C.L. Jr., Speiser D.E. Progress and controversies in developing cancer vaccines. J Transl Med. 2005. 3(1): 18-26.
8. Conry R.M., LoBuglio A.F., Loechel F. et al. A carcinoembrypnic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 1995. 2(1): 59-65.
9. Livingston P.O. Approaches to augmenting the immunogenecity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev. 1995. 145(1): 147-166.
10. Baldueva I.A. Protivoopuholevye vakciny. Prakticheskaja onkologija. 2003. 4(3): 157-166 [in Russian].
11. Mosca P.J., Hobeika A.C., Clay T.M. et al. Direct detection of cellular immune responses to cancer vaccines. Surgery. 2001. 129(3): 248-254.
12. Mitchell M.S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol. 1998. 25(6): 623-635.
13. Moingeon G. Cancer vaccines. Vaccine. 2001. 19(11-12): 1305-1326.
14. Chen Y.T. Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J. 2000. Vol. 6, Suppl 3. P. 208-217.
15. Engelhard V.H., Bullock T.N., Colella T.A., Mullins D.W. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer J. 2000. Vol 6, Suppl 3. P. 272-280.
16. Gordan J.D., Vonderheide R.H. Universal tumor antigens as targets for immunotherapy. Cytotherapy. 2002. 4(4): 317-327.
17. Liu M., Acres B., Balloul J.-M. et al. Gene-based vaccines and immunotherapeutics. PNAS. 2004. Vol. 101, suppl. 2. P. 14567-14571.
18. Harris J.E., Ryan L., Hoover H.C.Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: eastern cooperative oncology group study E5283. J Clin Oncol. 2000. 18(1): 148-157.
19. Hoover H.C.Jr., Brandhorst J.S., Peters L.C. et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993. 11(3): 390-399.
20. Repmann R., Goldschmidt A.J., Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res. 2003. 23(2A): 969-974.
21. Berd D., Maguire H.C.Jr., Schuchter L.M. et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 1997. 15(6): 2359-2370.
22. Berd D., Kairys J., Dunton C. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998. Vol. 25. P. 646-653.
23. Berd D., Sato T., Cohn H. et al. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer. 2001. 94(4): 531-539.
24. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther. 2002. 2(3): 335-342.
25. Berd D., Sato T., Maguire H.C.Jr. et al. Immunopharmacologic analysis of an autologous, hapten-odified human melanoma vaccine. J Clin Oncol. 2004. 22(3): 403-415.
26. Hersey P., Coates A.S., McCarthy. W.H. et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol. 2002. 20(20): 4181-4190.
27. Ockert D., Schirrmacher V., Beck N. et al. Newcastle disease virus_infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996. 2(1): 21-28.
28. Schirrmacher V., Haas C., Bonifer R. et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999. 6(1): 63-73.
29. Hanna M.G.Jr., Hoover H.C.Jr., Vermorken J.B. et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001. 19(17-19): 2576-2582.
30. Ransom J.H., Pelle B.A., Hubers H. et al. Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheralblood lymphocytes from patients immunized with an autologous tumor-cell with Bacillus Calmette-Querin vaccine. Int J Cancer. 1993. 54(5): 734-740.
31. Vermorken J.B., Claessen A.M., van Tinteren H. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999. 353(9150): 345-350.
32. Salgia R., Lynch T., Skarin A. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003. 21(4): 624-630.
33. Simons J.W., Mikhak B., Chang J.F. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999. 59(20): 5160-5168.
34. Soiffer R., Lynch T., Mihm M. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Nat Acad Sci USA. 1998. 95(22): 13141-13146.
35. Soiffer R., Hodi F.S., Haluska F. et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003. 21(17): 3343-3350.
36. Jocham D., Richter A., Hoffmann L. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004. 363(9409): 594-599.
37. Kuang M., Peng B.G., Lu M.D. et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for post- surgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004. 10(5): 1574-1579.
38. Uyl-de Groot C.A., Vermorken J.B., Hanna M.G.Jr. et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005. 23(17-18): 2379-2387.
39. Greten T.F., Jaffee E.M. Cancer vaccines. J Clin Oncol. 1999. 17(3): 1047-1060
40. McCune C.S., O'Donnell R.W., Marquis D.M., Sahasrabud he D.M. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother. 1990. 32(1): 62-66.
41. Sinkovics J.G. Viral oncolysates as human tumor vaccine. Int Rev Immunol. 1991. Vol. 7. P. 259-287.
42. Sivanandham M., Ditaranto K., Shaw P. et al. A phase III randomized, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with melanoma — an overview. Vaccone Res. 1996. Vol. 5. P. 215-222.
43. Wallack M.K., Sivanandham M., Balch C.M. et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998. 187(1): 69-77.
44. Liang W., Wang H., Sun T.M. et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003. 9(3): 495-498.
45. Schirrmacher V., Feuerer M., Beckhove P. et al. T cell memory, anergy and immunotherapy in breast cancer. J Mammary Gland Biol Neoplasia. 2002. 7(2): 201-208.
46. Schneider T., Gerhards R., Kirches E., Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol. 2001. 53(1): 39-46.
47. Luiten R.M., Kueter E.W., Mooi W. et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol. 2005. 23(35): 8978-8991.
48. Dillman R.O., Beutel L.D., De Leon C., Nayak S.K. Shortterm tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer. Cancer Biother Radiopharm. 2001. 16(3): 205-211.
49. Dillman R.O., Wiemann M., Nayak S.K. et al. Interferongamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother. 2003. 26(4): 367-373.
50. Shawler D.L., Bartholomew R.M., Garrett M.A. et al. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin Exp Immunol. 2002. 129(1): 99-106.
51. Eaton J.D., Perry M.J., Nicholson S. et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormonerefractory prostate cancer. BJU Int. 2002. 89(1): 19-26.
52. Elliott G.T., McLeod R.A., Perez J. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine in the treatment of disseminated malignant melanoma. Semin Surg Oncol. 1993. 9(3): 264-272.
53. Vaishampayan U., Abrams J., Darrah D. et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res. 2002. 8(12); 3696-3701.
54. Arienti F., Sule-Suso J., Belli F. et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther. 1996. 7(16): 1955-1963.
55. Maio M., Fonsatti E., Lamaj E. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother. 2002. 51(1): 9-14.
56. O'Rourke M.G., Johnson M., Lanagan C. et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003. 52(6): 387-395.
57. Katano M., Morisaki T., Koga K. et al. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 2005. 25(6A): 3771-3776.
58. Nestle F.O., Alijagic S., Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998. 4(3): 328-332.
59. Lee W.C., Wang H.C., Hung C.F. et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005. 28(5): 496-504.
60. Yu J.S., Liu G., Ying H. et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004. 64(14): 4973-4979.
61. Pandha H.S., John R.J., Hutchinson J. et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int. 2004. 94(3): 412-418.
62. Hirschowitz E.A., Foody T., Kryscio R. et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004. 22(14): 2808-2815.
63. Avigan D., Vasir B., Gong J. et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004. 10(14): 4699-4708.
64. Kugler A., Stuhler G., Walden P. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000. 6(3): 332-336.
65. Srivastava P.K., Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 1994. 6(5): 728-732.
66. Mazzaferro V., Coppa J., Carrabba M.G. et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003. 9(9): 3235-3245.
67. Ludewig B., Ochsenbein A.F., Odermatt B. et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med. 2000. 191(5): 795-804.
68. Panelli M. C., Wunderlich J., Jeffries J. et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000. 23(4): 487-498.
69. Zajchuk V.V., Potebnja G.P., Lisovenko G.S. ta in. Efektyvnist' zastosuvannja protypuhlynnoi' autovakcyny v kompleksnomu likuvanni hvoryh na rak molochnoi' zalozy II stadii'. Onkologija. 2004. 6(1): 52-58 [in Ukrainian].
70. Zatula D.G. Mikroorganizmy, rak i protivoopuholevyj immunitet. Kyiv: Nauk. dumka, 1985 [in Russian].
71. Kolesnik E.A., Potebnja G.P., Kikot' V.A. i dr. Protivoopuholevaja autovakcina v lechenii bol'nyh rasprostranennym kolorektal'nym rakom. Onkologija. 1999. 1(2): 104-109 [in Russian].
72. Potebnja G.P., Smolanka I.I., Lisovenko G.S. i dr. Jeffektivnost' immunoterapii autovakcinoj v lechenii bol'nyh rakom legkogo. Onkologija. 2000. 2(3): 191-194 [in Russian].
73. Potebnja G.P., Tanasijenko O.A., Lisovenko G.S., Savcova Z.D. Vykorystannja cytotoksychnyh lektyniv bakterial'nogo pohodzhennja v imunoterapii' eksperymental'nyh puhlyn. V: Struktura i biologichna aktyvnist' bakterial'nyh biopolimeriv. Kyiv: Kyi'vs'kyj universytet, 2003 : 235-304 [in Ukrainian].
74. Potebnja G.P., Skljar S.Ju., Bendjug G.D. ta in. Vykorystannja protypuhlynnoi' autovakcyny pry kompleksnomu likuvanni hvoryh na rak molochnoi' zalozy. Ukrhimioterap zhurnal. 2003. 17(2): 48-52 [in Ukrainian].
75. Chornyj V.O., Potebnja G.P., Lisovenko G.S. ta in. Perspektyvy zastosuvannja protypuhlynnoi' autovakcyny v likuvanni hvoryh na poshyrenyj rak shlunka. Onkologyja. 2003. 5(2): 107-110 [in Ukrainian].
76. Cmolanka I.I. Kombinovane likuvannja hvoryh na rak legeni. Avtoref. dys. d-ra byol.nauk: 14.01.07. Ynt onkologii' AMN Ukrai'ny. Kyi'v, 2001 [in Ukrainian].
77. Schulof R.S., Mai D., Nelson M.A. et al. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer. Mol Biother. 1988. 1(1): 30-36.
78. Butts C., Murray N., Maksymiuk A. et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005. 23(27): 6674-6681.
79. Emens L.A., Reilly R.T., Jaffee E.M. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocrine-Related Cancer. 2005. Vol. 12. P. 1-17.
80. Peoples G.E., Gurney J.M., Hueman M.T. et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005. 23(30): 7536-7545.
81. Potebnja G.P., Skljar S.Ju., Bendjug G.D. ta in. Vlyjanye autovakcyni na pokazately ymmunnoj systemi y gormonal'nij gomeostaz pry kompleksnom lechenyy bol'nih rakom molochnoj zhelezi. Onkologija. 2004. 6(3): 175-179 [in Ukrainian].
82. Diederichsen A.C., Stenholm A.C., Kronborg O. et al. Immunization of colorectal cancer patients with autologous tumor cells. Oncol Rep. 1998. 5(4): 823-826.
83. Mosolits S., Ullenhag G., Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005. 16(6): 847-862.
84. Potebnja G. P., Semernikov V. A., Hutornoj S. V. i dr. Vlijanie protivoopuholevoj autovakciny na nekotorye pokazateli immunnogo statusa bol'nyh s adenokarcinomoj prjamoj kishki. Jeksperim onkol. 2001. 23(3): 189-192 [in Russian].
85. Potebnja G. P., Semernikov V. A., Hutornoj S. V. i dr. Moduljacija antigennyh svojstv opuholevyh kletok s pomoshh'ju produktov metabolizma Bac. Mesentericus AB-56. Jeksperim onkol. 1999. 21(3-4): 223-227 [in Russian].
86. Potebnya G.P., Tanasienko O.A., Titova G.P. et al. Specifity and biological activity of cytotoxic lectins synthesized by Bacillus subtilis B-7025. Exp Oncol. 2002. 24(2): 150-152.